Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during past five years, boasting impressive response rates and durable remissions for patients who previously had no viable options. In this review, we provide a brief historical overview their development. We focus on practical aspects patient’s journey through unique toxicities current best practices to manage those. then discuss key registration trials that led approvals relapsed/refractory acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle (MCL), multiple myeloma. Finally, consider future development research directions cutting edge therapy.